Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?

Younossi, Zobair M., Paik, James M., Al Shabeeb, Reem, Golabi, Pegah, Younossi, Issah, Henry, Linda · 2022 · Hepatology

Abstract

Background: Given the association of NAFLD with metabolic risks, a name change to MAFLD is proposed. We compared the long‐term outcomes of NAFLD and MAFLD. Methods: We included patients with fatty liver disease (FLD) from NHANES III and NHANES 2017–2018 (FLD defined as moderate to severe hepatic steatosis by ultrasound for NHANES III and as having a controlled attenuation parameter ≥285 dB/m for NHANES 2017–2018). NAFLD was defined as FLD without other liver diseases and excess alcohol use. Metabolic‐associated fatty liver disease (MAFLD) was defined as FLD and metabolic dysfunction per criteria. All NHANES III participants had linked mortality data through December 31, 2015. Results: NHANES III participants (n = 12,878): mean age 43.1 years old; 49.5% male; 20.3% with FLD, 16.5% with NAFLD, and 18.1% with MAFLD. NHANES 2017–2018 participants (n = 4328): mean age 48.0 years old; 49.1% male; 36.8% with FLD, 34.2% with NAFLD, and 36.3% with MAFLD. Excellent concordance was noted between MAFLD and NAFLD diagnosis in both data sets (kappa coefficient = 0.83–0.94). Except for components of each definition (e.g., alcohol use for MAFLD), no other major differences in clinical characteristics were noted. During up to 27 years of follow‐up (median of 22.8 years), no differences in cumulative all‐cause and cause‐specific mortality were noted. In addition to the stage of fibrosis, insulin resistance was a predictor of liver mortality in NAFLD, and alcohol‐associated liver disease (ALD) was a predictor of mortality in MAFLD. Conclusions: MAFLD and NAFLD have similar clinical profiles and long‐term outcomes. The increased liver‐related mortality among NAFLD is driven by insulin resistance, and among MAFLD is primarily driven by ALD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.32499

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 182

Metadata

Authors
Younossi, Z. M., Paik, J. M., Al Shabeeb, R., Golabi, P., Younossi, I., & Henry, L.
Venue
Hepatology
Published
2022-05-02
Volume
76
Issue
5
Pages
1423-1437
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W4220821646
Cited by
182
References
6
FWCI
25.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease? https://app.cochat.ai/papers/10.1002/hep.32499
The paper
Younossi, Z. M., Paik, J. M., Al Shabeeb, R., Golabi, P., Younossi, I., & Henry, L. (2022). Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease? Hepatology. https://doi.org/10.1002/hep.32499

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.